ARAY ACCURAY INC

Nasdaq accuray.com


$ 1.73 $ -0.06 (-3.41 %)    

Tuesday, 14-Oct-2025 18:24:34 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 1.7
$ 1.74
$ 1.67 x 50
$ 1.80 x 5,500
$ 1.67 - $ 1.76
$ 1.14 - $ 2.95
695,795
na
191.55M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-28-2025 06-30-2025 10-K
2 05-02-2025 03-31-2025 10-Q
3 02-05-2025 12-31-2024 10-Q
4 11-06-2024 09-30-2024 10-Q
5 09-19-2024 06-30-2024 10-K
6 05-08-2024 03-31-2024 10-Q
7 02-07-2024 12-31-2023 10-Q
8 11-07-2023 09-30-2023 10-Q
9 09-07-2023 06-30-2023 10-K
10 05-08-2023 03-31-2023 10-Q
11 02-02-2023 12-31-2022 10-Q
12 11-03-2022 09-30-2022 10-Q
13 08-17-2022 06-30-2022 10-K
14 04-29-2022 03-31-2022 10-Q
15 01-28-2022 12-31-2021 10-Q
16 11-04-2021 09-30-2021 10-Q
17 08-17-2021 06-30-2021 10-K
18 04-30-2021 03-31-2021 10-Q
19 02-01-2021 12-31-2020 10-Q
20 11-04-2020 09-30-2020 10-Q
21 08-25-2020 06-30-2020 10-K
22 05-08-2020 03-31-2020 10-Q
23 02-04-2020 12-31-2019 10-Q
24 11-06-2019 09-30-2019 10-Q
25 08-23-2019 06-30-2019 10-K
26 05-09-2019 03-31-2019 10-Q
27 02-08-2019 12-31-2018 10-Q
28 11-06-2018 09-30-2018 10-Q
29 08-24-2018 06-30-2018 10-K
30 05-02-2018 03-31-2018 10-Q
31 02-05-2018 12-31-2017 10-Q
32 11-03-2017 09-30-2017 10-Q
33 08-25-2017 06-30-2017 10-K
34 05-05-2017 03-31-2017 10-Q
35 02-03-2017 12-31-2016 10-Q
36 11-01-2016 09-30-2016 10-Q
37 08-24-2016 06-30-2016 10-K
38 04-29-2016 03-31-2016 10-Q
39 02-01-2016 12-31-2015 10-Q
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 accuray-announces-first-patients-treated-through-5d-clinics-in-melbourne-using-cyberknife-s7-system

5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Ra...

 accuray-and-uw-smph-sign-mou-to-advance-online-adaptive-radiotherapy-on-accuray-helical-radiation-treatment-delivery-platform

Accuray Incorporated (NASDAQ:ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced tod...

 accuray-inc-advances-adaptive-radiotherapy-with-introduction-of-accuray-stellar-solution

New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive ...

 btig-maintains-buy-on-accuray-raises-price-target-to-5

BTIG analyst Maria Thibault maintains Accuray (NASDAQ:ARAY) with a Buy and raises the price target from $4 to $5.

 accuray-sees-fy2026-sales-471000m-485000m-vs-454740m-est

Accuray (NASDAQ:ARAY) sees FY2026 sales of $471.000 million-$485.000 million vs $454.740 million analyst estimate.

 accuray-q4-eps-001-misses-002-estimate-sales-127543m-beat-123774m-estimate

Accuray (NASDAQ:ARAY) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 44...

 accuray-lowers-fy2025-sales-guidance-from-46300m-47500m-to-45200m-46000m-vs-46830m-est

Accuray (NASDAQ:ARAY) lowers FY2025 sales outlook from $463.00 million-$475.00 million to $452.00 million-$460.00 million vs $4...

 accuray-q3-eps-001-beats-005-estimate-sales-11324m-beat-10153m-estimate

Accuray (NASDAQ:ARAY) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80...

 accuray-announced-that-new-data-on-the-clinical-use-of-the-cyberknife-system-reinforce-the-devices-broad-based-radiation-treatment-capabilities-for-central-nervous-system-tumors

SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatm...

 accuray-q2-earnings-assessment
Accuray Q2 Earnings Assessment
02/05/2025 21:56:30

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION